NCT03125642
Auto Stem Cell Transplant for Lymphoma Patients
At risk: Primary completion moved 12 months later.
See at-risk trials from Masonic Cancer Center, University of Minnesota
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 14 versions: 6 with changes below, 8 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Sep 30, 2026 to Sep 30, 2027
- Eligibility criteria expanded, about 46 words
- Study completion pushed from Apr 30, 2027 to Apr 30, 2028
- Notable Primary completion date: Sep 30, 2025 to Sep 30, 2026
- Study completion date: Apr 30, 2026 to Apr 30, 2027
- Notable Primary completion date: Sep 30, 2023 to Sep 30, 2025v11
- Minor Primary completion date: Apr 30, 2023 to Sep 30, 2023v10
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Apr 26, 2017 to Apr 20, 2017
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (5)
Arms and interventions
BCNU, etoposide, Ara-C and melphalan (BEAM) for all NHL and those HL patients who are unable to receive CBV
Cyclophosphamide, BCNU and VP-16 (CBV) for HL patients
Cyclophosphamide/Total Body Irradiation (CY/TBI) for patients with recent history of CNS lymphoma or those with allergies/contra-indications to agents used in BEAM
Drugs: Etoposide, BCNU, AraC, Melphalan, Cyclophosphamide
Procedures: Peripheral blood stem cell transplantation
Biologicals: G-CSF
Radiation: Total Body Irradiation
Sites
1 site in 1 country
- Masonic Cancer Center, University of MinnesotaMinneapolis, Minnesota, United States